ADAPTSMART (a Sustainable, Multi-stakeholder Approach from Research to Treatment-outcomes)
This unique IMI (Innovative Medicines Initiative) funded 30-month project investigates the emerging ‘adaptive development’ pathway to medicines in Europe. This joint public-private partnership will foster the development of Medicines Adaptive Pathways to Patients (MAPPs) in Europe, in finding a sustainable solution to balance early patient access and evidential trade-off regarding innovative therapies. It consists of 32 organisations and brings together patients, regulators, industry, Health Technology Assessment (HTA) bodies, payers, and academics in early multi-stakeholder dialogue.
Started in Sept 2015, this work extends previous CASMI and IMI work investigating key concepts and concerns around adaptive pathways, in exploring a variety of themes, concepts and recommendations to facilitate MAPPs implementation. Under the current programme of work, CASMI is co-leading 1 of 4 work packages and 7 separate work streams including; evidence generation across the product lifecycle, ethical and legal considerations, resource mobilisation, prescription control, and intellectual property and regulatory data exclusivity.
The project is due to finish early 2018, with all published findings on the below link.
To visit the website and view project outputs click here http://adaptsmart.eu/
IMI ADAPT SMART has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115890. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
For more information, please contact Dr Stuart Faulkner.